These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 28703335)
1. GATA3 as a putative marker of breast cancer metastasis-A retrospective immunohistochemical study. De Lara S; Parris TZ; Werner Rönnerman E; Helou K; Kovács A Breast J; 2018 Mar; 24(2):184-188. PubMed ID: 28703335 [TBL] [Abstract][Full Text] [Related]
2. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123 [TBL] [Abstract][Full Text] [Related]
3. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens. Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624 [TBL] [Abstract][Full Text] [Related]
4. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors. Yang Y; Lu S; Zeng W; Xie S; Xiao S Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704 [TBL] [Abstract][Full Text] [Related]
5. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Lew M; Pang JC; Jing X; Fields KL; Roh MH Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236 [TBL] [Abstract][Full Text] [Related]
6. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases. Lionti S; La Rocca L; Nunnari CM; Barresi V Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951 [TBL] [Abstract][Full Text] [Related]
7. Markers of metastatic carcinoma of breast origin. Gown AM; Fulton RS; Kandalaft PL Histopathology; 2016 Jan; 68(1):86-95. PubMed ID: 26768031 [TBL] [Abstract][Full Text] [Related]
8. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Shield PW; Papadimos DJ; Walsh MD Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220 [TBL] [Abstract][Full Text] [Related]
9. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
10. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression. Hafez NH; Shaaban HM Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613 [TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of the combined use of HNF4A and GATA3 in distinction between primary and metastatic breast and gastric carcinomas. Saad DZ; Sidhom KF; Gadallah MF; Samir NA; Shakweer MM APMIS; 2021 Sep; 129(9):548-555. PubMed ID: 34120367 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung. Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644 [TBL] [Abstract][Full Text] [Related]
13. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases. Boto A; Harigopal M Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697 [TBL] [Abstract][Full Text] [Related]
14. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens. Braxton DR; Cohen C; Siddiqui MT Diagn Cytopathol; 2015 Apr; 43(4):271-7. PubMed ID: 25088841 [TBL] [Abstract][Full Text] [Related]
15. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin. Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362 [TBL] [Abstract][Full Text] [Related]
16. Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance. Kong X; Wang Q; Li J; Li M; Deng F; Li C Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35388661 [TBL] [Abstract][Full Text] [Related]
17. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
18. Evaluating the utility of trefoil factor 1 as a mammary-specific immunostain compared and in conjunction with GATA-3 and mammaglobin in the distinction between carcinoma of breast and lung. Wells JM; Ginter PS; Liu Y; Chen Z; Narula N; Shin SJ Am J Clin Pathol; 2015 Sep; 144(3):444-51. PubMed ID: 26276775 [TBL] [Abstract][Full Text] [Related]
19. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma. Bradt A; Jing X; Smola BS; Lew M Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248 [TBL] [Abstract][Full Text] [Related]
20. Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer. Kriegsmann K; Zgorzelski C; Muley T; Christopoulos P; von Winterfeld M; Herpel E; Goeppert B; Mechtersheimer G; Sinn P; Stenzinger A; Schirmacher P; Winter H; Eichinger M; Warth A; Kriegsmann M Histopathology; 2020 Dec; 77(6):900-914. PubMed ID: 32634256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]